HR+/HER2- EARLY BREAST CANCER
Clinical trials for HR+/HER2- EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Coaching may boost adherence to breast cancer therapy
Disease control Recruiting nowThis study tests whether personalized coaching based on patient typology helps women with HR+/HER2- early breast cancer stick with their ribociclib treatment longer. About 548 participants will either receive standard education or tailored coaching using a validated tool. The goa…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: NA • Sponsor: Institut fuer Frauengesundheit • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can ribociclib keep breast cancer from coming back? new study tracks Real-World results
Disease control Recruiting nowThis study follows about 3,250 people with HR+/HER2- early breast cancer who are at high risk of recurrence. Participants take ribociclib (Kisqali) plus an aromatase inhibitor as part of their routine care. Researchers will track how well the treatment works in real life, its sid…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Real-World study tracks Ribociclib's impact on early breast cancer
Disease control Recruiting nowThis study follows 177 people with HR+/HER2- early breast cancer who are already taking ribociclib with hormone therapy as part of their routine care. Researchers will track how well the treatment works and any side effects over time. The goal is to see if the drug helps prevent …
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Breast cancer trial lets early response guide treatment switch
Disease control Recruiting nowThis phase II study tests a personalized approach for women with a common type of early breast cancer (HR+/HER2-). All 45 participants start with a combination of culmerciclib and hormone therapy. If the tumor responds well, they continue; if not, they switch to a different treat…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New breast cancer trial aims to skip chemo for some patients
Disease control Recruiting nowThis study tests a new drug called fovinaciclib combined with hormone therapy and targeted antibodies in people with early-stage HR-positive/HER2-positive breast cancer. After 6 weeks, doctors check if the tumor is shrinking. If it is, patients continue the same treatment; if not…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for High-Risk breast cancer: drug combo aims to stop recurrence
Disease control Recruiting nowThis study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from coming back in high-risk patients with HR+/HER2+ early breast cancer. About 1,900 women aged 18-70 who have already completed anti-HER2 therapy will be randomly assi…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New study tracks breast cancer return in patients on targeted therapy
Knowledge-focused Recruiting nowThis study observes 750 people with a common type of breast cancer who have already been treated with surgery and are now taking CDK4/6 inhibitors to lower the risk of cancer coming back. Researchers will track how many patients experience a relapse and how well they do over time…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Breast cancer drug adherence under the microscope: will patients stick with treatment?
Knowledge-focused Recruiting nowThis observational study tracks 200 women with high-risk HR+/HER2- early breast cancer to see how many continue taking abemaciclib six months after starting. Researchers will review therapy data from 2023 to 2025. The goal is to understand real-world persistence, not to test a ne…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Institut fuer Frauengesundheit • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC